Sumitomo Mitsui DS Asset Management Company Ltd Has $2 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 28.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,370 shares of the life sciences company’s stock after buying an additional 3,393 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Illumina were worth $2,004,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ILMN. Trivant Custom Portfolio Group LLC increased its holdings in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after purchasing an additional 125 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina during the 2nd quarter valued at $34,000. Massmutual Trust Co. FSB ADV grew its holdings in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares during the period. Finally, Itau Unibanco Holding S.A. bought a new stake in Illumina in the second quarter valued at $61,000. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.6 %

Shares of Illumina stock opened at $145.21 on Tuesday. The stock has a fifty day moving average price of $133.15 and a 200-day moving average price of $121.24. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market cap of $23.13 billion, a PE ratio of -17.82 and a beta of 1.15. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $151.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 earnings per share. Equities research analysts anticipate that Illumina, Inc. will post 3.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ILMN. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research note on Wednesday, August 28th. Leerink Partners increased their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Royal Bank of Canada restated an “outperform” rating and set a $252.00 price objective on shares of Illumina in a report on Thursday, October 10th. Stephens reiterated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a report on Wednesday, July 10th. Finally, TD Cowen upgraded shares of Illumina from a “hold” rating to a “buy” rating and boosted their price target for the company from $126.00 to $144.00 in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $154.33.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.